Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
Y. Lu, Q. Yang, T. Ran, G. Zhang, W. Li, P. Zhou, J. Tang, M. Dai, J. Zhong, H. Chen, P. He, A. Zhou, B. Xue, J. Chen, J. Zhang, , J. Shang
The paper identifies a potent orally bioavailable SARS-CoV-2 PLpro inhibitor with in vitro and in vivo antiviral activity against SARS-CoV-2 and related coronaviruses.
bioRxiv · Apr 3, 2024Microbiology